Stevanato(OMPI) Nexa® Vials 西林瓶具有卓越的機械阻力,可提高效率和安全性
廠商名稱:昱新先進股份有限公司
發佈日期:2025-05-22
攤位號碼:M1011
JAN 8 | 2025
The Superior Mechanical Resistance of Nexa® Vials for Improved Efficiency and Safety
Executive Summary
Introduction: Ensuring the mechanical resistance of pharmaceutical glass vials is crucial for safe and efficient drug delivery. While allowing for high throughput and efficiency, the bulk Fill & Finish process exerts high level of stress on glass containers, such as glass-to-glass contact and vertical loads, which can lead to cosmetic defects and breakages. Superior vial quality mitigates the negative impact of this stress, improving filling process performance and output as well as reducing the risk of container breakage during transport.
This study aims to experimentally demonstrate the improved mechanical resistance performance of Nexa®. By comparing the 2R ISO format vial in Nexa® and Fina® platforms, this study highlights how Nexa® vials provide superior mechanical resistance, which translates into several operational benefits.
Test Methodology
Mechanical resistance was assessed using two quantitative techniques
1. Vertical Compression Test (VC): This test measures the maximum force a vial can withstand before failure when subjected to axial stress.
Figure 1: Sample before (left) and after (right) VC test.
2. Burst Test (BT): This test is performed to apply internal pressure to the glass container to obtain its maximum value of internal pressure resistance.
Figure 2: Sample before (left) and after (right) the burst test.
Both tests compared Nexa® and Fina® vials. From the results achieved (VC and BT), Nexa® vials showed consistent superior mechanical resistance.
Key Results
2R ISO vials
- In the Vertical Compression Test, Nexa® vials demonstrated an average maximum force of at least 3x Fina®.
Figure 3: Boxplot of Vertical Compression results for 2R Fina® and Nexa® vials.
- In the Burst Test, Nexa® vials are characterized by a higher mean value, in terms of maximum pressure, than Fina® vials.
Figure 4: Boxplot of Burst Test Results for 2R Fina® and Nexa® vials
Operational Benefits of Nexa® Vials - Thanks to their improved cosmetic quality and mechanical resistance, Nexa® vials provide several advantages:
01 Reduced Total Cost of Ownership (TCO): Fewer cosmetic rejections and in-line breakages reduce waste of both container and final product, which in turn lowers costs and prevents lost revenues.
02 Improved Efficiency: Nexa® vials result in fewer lines-stops, downtimes, and labor required to fix the filling line after breakage occurrence.
03 Higher Safety: The superior mechanical strength of Nexa® vials reduces the risk of harmful products being dispersed due to container breakage.
Conclusions
This study analyzed the improved mechanical resistance of Nexa® vials by comparing them to Fina® vials through vertical compression (VC) and burst test (BT). According to the results achieved, Nexa® vials have superior mechanical resistance, even 3x Fina® with regards to Vertical compression (VC).
Thanks to its improved mechanical resistance, the Nexa® vial platform offers advantages in terms of:
01 Lower risk of breakage and cosmetic rejections reducing non-quality costs, and maximizing redictivity of high-value drug products
02 Lower risk of breakage to preserve people’s safety when dealing with cytotoxic products and to guarantee container integrity during challenging freezing processes.
Nexa® vial platform is Stevanato Group next level of quality specifically designed for most of high value products such as biotech, high-value vaccines, cytotoxic and next generation drugs.
Thanks to their improved mechanical resistance and cosmetic quality Nexa® vials minimize product waste and product release into the environment during fill & finish process and final visual inspection.
Additionally, Nexa® vials ensure lower vial breakage risk at challenging temperatures during freezing and cryo treatments.
更多參展商新聞稿
- 國立妝品科系打造台灣化粧品合規服務第一品牌 國立臺南護理專科學校 / 2025-05-25
- SHIBUYA 打造再生醫療製劑智慧量產平台 推動產業邁向自動化與數位化 宏騏實業股份有限公司 / 2025-05-23
- 國立成功大學基因體醫學中心榮獲2024國家新創精進獎 成大基因體醫學中心 / 2025-05-23
- AB DigiHealth攜手美基生技 推動「智慧優質胚胎預測系統」 成大基因體醫學中心 / 2025-05-23
- AB DigiHealth 在 BIO 2024 展出最新研發 AI 軟體醫材icONE,應用於不孕 成大基因體醫學中心 / 2025-05-23
- 源自日本的DC直流馬達技術,富泰空調設備是穩定、省電工業設備的首選 富泰空調科技股份有限公司 / 2025-05-23
- 盟基生技 - 引領台灣生技群、提供多元且高技術性的客製化服務 盟基生物科技股份有限公司 / 2025-05-23
- 創甡生技的使命與價值主張 創甡生物科技股份有限公司 / 2025-05-22
- 弘光科大教授研發促進糖尿病傷口癒合藥物 獲國際發明賽金牌 弘光科技大學 / 2025-05-22
- 上海百英生物科技股份有限公司介紹 盟基生物科技股份有限公司 / 2025-05-22
- Promega能量代謝與細胞檢測試劑套組,助攻代謝研究與即時活性觀察 —— 勁因科技誠摯推薦 勁因科技有限公司 / 2025-05-21
- 潤霈生技2025台灣再生醫學會盛大展出 眾多產品會場吸睛 迴響熱烈 潤霈生技股份有限公司 / 2025-05-21
- 潤霈生技結合學界、醫界 開啟醫美應用新領域 潤霈生技股份有限公司 / 2025-05-21
- 潤霈生技美容保養展盛大展出 產銷俱優、多元布局搶攻更大醫美版圖 潤霈生技股份有限公司 / 2025-05-21
- Elabscience-生命科學及健康領域最值得信賴的品牌 武漢伊萊瑞特生物科技股份有限公司 / 2025-05-21
- EG BioMed 力挺胰臟癌防治,參與 PurpleStride 2025 年度公益活動 愛立基生醫股份有限公司 / 2025-05-20
- 專利+國際認證!EG BioMed DNA 甲基化血液檢測,助攻癌症早期偵測 愛立基生醫股份有限公司 / 2025-05-20
- 前進亞洲生技大展! 芯元生醫攜創新適體技術打造精準檢測新格局 莉蒔科技股份有限公司 / 2025-05-20
- Getinge Life Science 產品線持續創新,推出新型 DPTE®-FLEX Alpha 台灣悅廷和有限公司 / 2025-05-20
- 昱新獨家代理 "法國PIERCAN" 乾燥箱手套或隔離器手套領域的全球領導 。 昱新先進股份有限公司 / 2025-05-20